Takeda reports second PhIII win for subcutaneous Entyvio as regulators review expanded use
Before consummating its $62 billion buyout of Shire, Takeda divested SHP647 — which the rare disease biotech was developing for ulcerative colitis — so it can retain its blockbuster drug Entyvio. In doing so the Japanese pharma took the opposite approach to Bristol-Myers, which found itself in a similar predicament but chose to bet on its own investigational drug over Celgene’s Otezla — a top seller that’s just expanded its label.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
